BACKGROUND: Lung transplantation continues to have poor long-term survival partly because of the high incidence of bronchiolitis obliterans syndrome (BOS). Gastroesophageal reflux disease (GERD) has been implicated in BOS pathogenesis. We investigated the role of collagen type V [col(V)] sensitization in this process. METHODS: Only primary lung transplant recipients were included. Reflux status was assessed with pH monitoring, impedance plethysmography, and esophagogastroduodenoscopy. Sensitivity to col(V) was determined with trans vivo delayed-type hypersensitivity reaction (DTH). Kaplan-Meier analyses were performed. RESULTS: Of the 54 recipients, 26 had proven GERD. There were no significant between-group differences in diagnosis; donor and recipient age; sex; ischemic time; single vs bilateral; human leukocyte antigen A, B, and DR matching cytomegalovirus status; acute rejections; or mean follow-up period. The mean DTH response in the GERD group was 25.7 x 10(-4) inches vs 18.3 x 10(-4) inches in the non-GERD group (P = .023). There was a significant reduction in BOS-free survival in the GERD group for both BOS-I (GERD+, 28.3%; GERD-, 86.6%; P = .0001) and BOS-II/III (GERD+, 66.2%; GERD-, 91.7%; P = .0374). A second cohort of 53 patients awaiting lung transplantation also was assayed. The mean DTH response in the GERD group was 24.0 x 10(-4) inches vs 13.1 x 10(-4) inches in the non-GERD group (P = .003). There were no differences in age or sex. CONCLUSIONS: GERD is strongly associated with the development of BOS after primary lung transplantation. Col(V) sensitization is associated with reflux and BOS and may play an intermediary role in the pathogenesis of BOS. Trials using col(V) reactivity to assess the impact of antireflux procedures in patients with lung transplantation and idiopathic pulmonary fibrosis are warranted.
BACKGROUND: Lung transplantation continues to have poor long-term survival partly because of the high incidence of bronchiolitis obliterans syndrome (BOS). Gastroesophageal reflux disease (GERD) has been implicated in BOS pathogenesis. We investigated the role of collagen type V [col(V)] sensitization in this process. METHODS: Only primary lung transplant recipients were included. Reflux status was assessed with pH monitoring, impedance plethysmography, and esophagogastroduodenoscopy. Sensitivity to col(V) was determined with trans vivo delayed-type hypersensitivity reaction (DTH). Kaplan-Meier analyses were performed. RESULTS: Of the 54 recipients, 26 had proven GERD. There were no significant between-group differences in diagnosis; donor and recipient age; sex; ischemic time; single vs bilateral; human leukocyte antigen A, B, and DR matching cytomegalovirus status; acute rejections; or mean follow-up period. The mean DTH response in the GERD group was 25.7 x 10(-4) inches vs 18.3 x 10(-4) inches in the non-GERD group (P = .023). There was a significant reduction in BOS-free survival in the GERD group for both BOS-I (GERD+, 28.3%; GERD-, 86.6%; P = .0001) and BOS-II/III (GERD+, 66.2%; GERD-, 91.7%; P = .0374). A second cohort of 53 patients awaiting lung transplantation also was assayed. The mean DTH response in the GERD group was 24.0 x 10(-4) inches vs 13.1 x 10(-4) inches in the non-GERD group (P = .003). There were no differences in age or sex. CONCLUSIONS: GERD is strongly associated with the development of BOS after primary lung transplantation. Col(V) sensitization is associated with reflux and BOS and may play an intermediary role in the pathogenesis of BOS. Trials using col(V) reactivity to assess the impact of antireflux procedures in patients with lung transplantation and idiopathic pulmonary fibrosis are warranted.
Authors: C M Burke; J Theodore; K D Dawkins; S A Yousem; N Blank; M E Billingham; A Van Kessel; S W Jamieson; P E Oyer; J C Baldwin Journal: Chest Date: 1984-12 Impact factor: 9.410
Authors: Denis Hadjiliadis; R Duane Davis; Mark P Steele; Robert H Messier; Christine L Lau; Steve S Eubanks; Scott M Palmer Journal: Clin Transplant Date: 2003-08 Impact factor: 2.863
Authors: M Azizul Haque; Teruaki Mizobuchi; Kazuhiro Yasufuku; Takehiko Fujisawa; Randy R Brutkiewicz; Yan Zheng; Kena Woods; Gerald N Smith; Oscar W Cummings; Kathleen M Heidler; Janice S Blum; David S Wilkes Journal: J Immunol Date: 2002-08-01 Impact factor: 5.422
Authors: Teruaki Mizobuchi; Kazuhiro Yasufuku; Yan Zheng; M Azizul Haque; Kathleen M Heidler; Kena Woods; Gerald N Smith; Oscar W Cummings; Takehiko Fujisawa; Janice S Blum; David S Wilkes Journal: J Immunol Date: 2003-08-01 Impact factor: 5.422
Authors: Edward Cantu; James Z Appel; Matthew G Hartwig; Hiwot Woreta; Cindy Green; Robert Messier; Scott M Palmer; R Duane Davis Journal: Ann Thorac Surg Date: 2004-10 Impact factor: 4.330
Authors: R Duane Davis; Christine L Lau; Steve Eubanks; Robert H Messier; Denis Hadjiliadis; Mark P Steele; Scott M Palmer Journal: J Thorac Cardiovasc Surg Date: 2003-03 Impact factor: 5.209
Authors: Nirmal S Sharma; Keith M Wille; S Athira; Degui Zhi; Kenneth P Hough; Enrique Diaz-Guzman; Kui Zhang; Ranjit Kumar; Sunad Rangarajan; Peter Eipers; Yong Wang; Ritesh K Srivastava; Jose Vicente Rodriguez Dager; Mohammad Athar; Casey Morrow; Charles W Hoopes; David D Chaplin; Victor J Thannickal; Jessy S Deshane Journal: J Heart Lung Transplant Date: 2017-07-15 Impact factor: 10.247
Authors: Satish Chandrashekaran; Cesar A Keller; Walter K Kremers; Steve G Peters; Matthew A Hathcock; Cassie C Kennedy Journal: J Heart Lung Transplant Date: 2014-11-17 Impact factor: 10.247
Authors: Ashwini Arjuna; Michael T Olson; Rajat Walia; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar Journal: Expert Rev Respir Med Date: 2020-10-25 Impact factor: 3.772
Authors: Lourdes Alcaide-Ruggiero; Verónica Molina-Hernández; María M Granados; Juan M Domínguez Journal: Int J Mol Sci Date: 2021-12-11 Impact factor: 5.923